CASE REPORT

Insight into the mechanisms of type III minocycline-induced pigmentation removal: A case of repeated immediate pigment clearing with the Q-switched 755-nm alexandrite laser over a 13-year period

Tiffany Y. Loh, MD, Matthew S. Goldberg, MD, R. R. Falsey, MD, Jennifer K. Barton, PhD, Paul Sagerman, MD, and Gerald N. Goldberg, MD

Tucson and Chandler, Arizona and New York, New York

Key words: immediate pigment lightening; minocycline-induced pigmentation; Q-switched alexandrite laser.

CASE REPORT

A 68-year-old man with rheumatoid arthritis presented for laser treatment of facial pigmentation (Fig 1, A). He had taken oral minocycline 100 mg 3 times weekly for 8 years (cumulative dose, 124.8 g) because of severe arthritic discomfort.

Physical examination showed patchy slate blue/grey hyperpigmentation of the face, gums, teeth, and nail beds, consistent with type III minocycline-induced pigmentation (MP). There was no pigmentation of sun-protected areas.

Two different laser modalities were tested before treatment: Q-switched 755 nm (Qs755nm) alexandrite (3.4 J/cm² with 4-mm spot size, 4.8 J/cm² with 3-mm spot size) and Q-switched 1064 nm (Qs1064nm) neodymium:YAG (yttrium aluminum garnet) (4.8 J/cm² with 3-mm spot size, 3 J/cm² with 4-mm spot size). Qs755nm at 2.0 Hz/4-mm spot/3.4 J/cm² showed the most improvement, with immediate pigment clearing, and was used for full facial treatment (3450 pulses). This setting was also selected because it had the largest spot size with lowest fluence, thus limiting the number of pulses and treatment time required. As observed with the test treatment, pigment resolution occurred immediately on the same day after therapy.

There were no significant postoperative complications. Pigment resolution was maintained at 13 months despite continued minocycline use, and the patient was highly satisfied (Fig 1, B).

The patient continued taking minocycline 100 mg 3 times weekly and re-presented 3 times over the next 13 years with facial hyperpigmentation (total cumulative dose of minocycline, 202.8 g). Each time, immediate pigment clearing was achieved with the Qs755nm alexandrite laser. Every visit concluded with a discussion that hyperpigmentation would recur with continued minocycline ingestion. At the time of this article’s writing, he continues to take minocycline.

Histopathology

The pretreatment biopsy showed intracellular and extracellular type III MP in the dermis, with notably no detectable change in the posttreatment biopsy.

However, in contrast to the pretreatment biopsy, the extracellular pigment in the posttreatment sample was no longer highlighted by Fontana-Masson (FM) stain, but intracellular pigment continued to

From the University of Arizona, Division of Dermatology, Tucson; Mt Sinai Hospital, Department of Dermatology, New York; East Valley Dermatology Center, Chandler; and University of Arizona, Department of Biomedical Engineering, Tucson.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Tiffany Y. Loh, MD, 7165 North Pima Canyon Dr, Tucson, AZ 85718. E-mail: tiffany.yv.loh@gmail.com.

JAAD Case Reports 2019;5:865-7.
2352-5126
© 2019 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2019.07.030
The change in melanin staining is consistent with the clinically observed reduction in pigment intensity.

DISCUSSION

Although minocycline is generally safe, cutaneous pigmentation is a common adverse effect. Type III is the least common MP, involving sun-exposed areas and staining positively only for melanin. It is often unremitting or requires multiple treatments to achieve improvement.

Although we are not the first to document successful Qs laser treatment of MP, our case is notable for the rapidity of pigment resolution repeated on multiple occasions over 13 years. In contrast to previous cases requiring multiple treatments, our patient experienced immediate and sustained cosmetic improvement after only 1 treatment. Although successful treatment of minocycline-related pigmentation has also been reported with newer picosecond lasers, these devices are more expensive and less accessible than the Qs alexandrite laser. Other reports have also described the treatment of minocycline-associated pigmentation with combination laser modalities. However, this is less convenient and more costly than using a single device such as the Qs alexandrite, as shown in our case. Because our patient continued to take minocycline, he did experience re-pigmentation; however, each recurrence resolved immediately with 1 treatment using the Qs755nm alexandrite laser, showing its effectiveness in achieving MP clearing.

The findings of our case are reminiscent of immediate pigment darkening resulting from ferric oxide (red-brown) reduction to ferrous oxide (black). We term our outcome immediate pigment lightening, which may be another example of Q-switched laser alteration of dermal pigmentation through a physicochemical mechanism.

The pigment in our case may be an insoluble minocycline-cation coordination complex, with calcium or magnesium as central metal ions. Because tetracyclines are susceptible to heat and photodecomposition, a physicochemical process that disrupts these complexes could explain our findings. Specifically, the discrepancy between H&E and FM stains suggests that extracellular pigment is still present after treatment but in an altered chemical state, such that it can no longer absorb visible light.

CONCLUSIONS

To our knowledge, this is the first case to show immediate pigment lightening of type III MP repeated over multiple instances using only the
Qs755nm alexandrite laser. We propose that an insoluble minocycline-cation coordination complex with selective sensitivity to the Qs755nm alexandrite laser may be deposited within the dermis. Our case shows that the Qs755nm alexandrite laser may be a preferable treatment modality for type III MP, especially because it is a single device and may be more convenient and cost effective compared with other laser modalities or combination laser treatments. Further studies investigating the mechanisms of MP deposition and resolution are warranted to clarify our findings.

REFERENCES

1. Mouton RW, Jordaan HF, Schneider JW. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol. 2004;29:8-14.
2. La Placa M, Infusino SD, Balestri R, Venceni C. Minocycline-induced blue-gray discoloration. Skin Appendage Disord. 2017;3:161-162.
3. Alster TS, Gupta SN. Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser. Dermatol Surg. 2004;30:1201-1204.
4. Green D, Friedman KJ. Treatment of minocycline-induced cutaneous pigmentation with the Q-switched alexandrite laser and a review of the literature. J Am Acad Dermatol. 2001;44(2 Suppl):S42-347.
5. Nisar MS, Iyer K, Brodell RT, Lloyd JR, Shin TM, Ahmad A. Minocycline-induced hyperpigmentation: comparison of 3 Q-switched lasers to reverse its effects. Clin Cosmet Investig Dermatol. 2013;31:159-162.
6. Sasaki K, Ohshiro T, Ohshiro T, et al. Type 2 minocycline-induced hyperpigmentation successfully treated with the novel 755-nm picosecond alexandrite laser—a case report. Laser Ther. 2017;26:137-144.
7. Rodrigues M, Bekhor P. Treatment of minocycline-induced cutaneous pigmentation with the picosecond alexandrite (755-nm) laser. Dermatol Surg. 2015;1179-1182.
8. Vangipuram RK, DeLozier WL, Geddes E, Friedman PM. Complete resolution of minocycline pigmentation following a single treatment with non-ablative 1550-nm fractional resurfacing in combination with the 755-nm Q-switched alexandrite laser. Lasers Surg Med. 2016;48:234-237.
9. Fitzpatrick RE, Lupton JR. Successful treatment of treatment-resistant laser-induced pigment darkening of a cosmetic tattoo. Lasers Surg Med. 2000;27:358-361.
10. Hassani M, Lazaro R, Perez C, Condon S, Pagan R. Thermostability of oxytetracycline, tetracycline, and doxycycline at ultrahigh temperatures. J Agric Food Chem. 2008;56:2676-2680.